Skip to content
RDL Network logo
Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial — Irene L. M. Reijers (2019) | RDL Network